Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Amneal Pharmaceuticals, Inc.    AMRX

AMNEAL PHARMACEUTICALS, INC.

(AMRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Amneal Shares Up Nearly 50% on FDA Nod for NuvaRing Generic

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/12/2019 | 01:51pm EST

By Colin Kellaher

Shares of Amneal Pharmaceuticals rose nearly 50% on Thursday after it received Food and Drug Administration approval for EluRyng, the first generic version of Merck & Co.'s (MRK) NuvaRing contraceptive.

The Bridgewater, N.J., pharmaceutical company said it was manufacturing EluRyng internally and launching the product Thursday.

Analysts at SVB Leerink said they expect the product will contribute about $35 million in sales and 2 cents in per-share earnings to Amneal next year, assuming no capacity constraints.

Shares of Amneal were recently up 49.4% to $5.20.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
AMNEAL PHARMACEUTICALS, INC. -2.54% 4.61 Delayed Quote.-1.87%
MERCK AND COMPANY 0.14% 86.1 Delayed Quote.-5.46%
MERCK KGAA -2.00% 117.6 Delayed Quote.13.91%
MRK HOLDINGS INC. -3.89% 247 End-of-day quote.10.76%
PROCTER & GAMBLE COMPANY 0.44% 125.69 Delayed Quote.0.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMNEAL PHARMACEUTICALS, IN
08:29aAMNEAL PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2019 Results on ..
AQ
01/24AMNEAL PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2019 Results on ..
BU
01/15AMNEAL PHARMACEUTICALS : JP Morgan 2020 Presentation
PU
01/15AMNEAL PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
AQ
2019AMNEAL PHARMACEUTICALS : to Present at the 38th Annual J.P. Morgan Healthcare Co..
BU
2019AMNEAL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regula..
AQ
2019AMNEAL PHARMACEUTICALS : Appoints Jeff George, John Kiely and Shlomo Yanai to Bo..
BU
2019AMNEAL PHARMACEUTICALS : Receives Abbreviated New Drug Application Approval for ..
AQ
2019Amneal Shares Up Nearly 50% on FDA Nod for NuvaRing Generic
DJ
2019Amneal Gets FDA OK for First Generic of Merck's NuvaRing
DJ
More news
Financials (USD)
Sales 2019 1 607 M
EBIT 2019 280 M
Net income 2019 -345 M
Debt 2019 2 440 M
Yield 2019 -
P/E ratio 2019 -1,26x
P/E ratio 2020 -1,86x
EV / Sales2019 1,91x
EV / Sales2020 1,78x
Capitalization 634 M
Chart AMNEAL PHARMACEUTICALS, INC.
Duration : Period :
Amneal Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMNEAL PHARMACEUTICALS, IN
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 4,82  $
Last Close Price 4,61  $
Spread / Highest target 51,8%
Spread / Average Target 4,52%
Spread / Lowest Target -34,9%
EPS Revisions
Managers
NameTitle
Chintu Patel Co-Chief Executive Officer & Director
Chirag K. Patel President & Co-Chief Executive Officer & Director
Paul M. Meister Chairman
Andrew S. Boyer Executive Vice President-Commercial Operations
Todd P. Branning Chief Financial Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AMNEAL PHARMACEUTICALS, INC.-1.87%634
JOHNSON & JOHNSON1.68%390 359
ROCHE HOLDING AG3.03%284 454
PFIZER1.63%220 369
MERCK AND COMPANY-5.46%218 904
NOVARTIS-0.38%213 484